Abstract
Elevated serum levels of homocysteine, a sulphur-containing amino acid, are increasingly recognized as an independent risk factor for atherosclerotic and thrombotic vascular disease. Presence of a thermolabile variant of methylenetetrahydrofolatereductase and an inadequate folate status are the most common causes of hyperhomocysteinaemia. Homocysteine damages the vessel wall mainly through generation of oxygen radicals and creates a prothrombotic environment. In the majority of cases, normalization of homocysteine levels can be achieved with administration of vitamins of the B-group. The effect of this treatment on cardiovascular outcome, however, remains undefined.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 337-344 |
| Number of pages | 8 |
| Journal | Acta cardiologica |
| Volume | 53 |
| Issue number | 6 |
| State | Published - Dec 1998 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Atherosclerosis
- Homocysteine
- Risk factor
- Screening
- Thrombosis
- Treatment
Fingerprint
Dive into the research topics of 'Mild to moderate hyperhomocysteinaemia in cardiovascular disease'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS